Related Experiment Video
Updated: Apr 12, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
32.7K
Mepolizumab for eosinophilic severe asthma: recent studies
Douglas S Robinson1, Harsha H Kariyawasam
1Department of Respiratory Medicine, Severe Asthma Service, UCLH NHS Foundation Trust, UCLH NHS Trust , 250 Euston Road, London NW1 , UK douglas.robinson@uclh.nhs.uk.
Expert Opinion on Biological Therapy
|May 9, 2015
Summary
Mepolizumab, an anti-interleukin-5 monoclonal antibody, significantly reduces asthma exacerbations and oral steroid use in severe eosinophilic asthma patients. This offers a new treatment option for difficult-to-control disease.
Area of Science:
- Respiratory Medicine
- Immunology
- Pharmacology
Background:
- Severe asthma is often characterized by eosinophilic inflammation.
- Interleukin-5 (IL-5) is a critical cytokine for eosinophil development and survival.
- Targeting the IL-5 pathway with monoclonal antibodies represents a therapeutic strategy for severe asthma.
Purpose of the Study:
- To evaluate the efficacy of mepolizumab in reducing exacerbations in severe asthma.
- To assess the impact of mepolizumab on oral corticosteroid requirements in severe asthma patients.
Main Methods:
- Two large clinical studies (MENSA and SIRIUS) investigated mepolizumab in severe asthma.
- Patients had persistent peripheral blood eosinophilia and symptoms despite standard therapy.
- Mepolizumab is an anti-IL-5 monoclonal antibody therapy.
Main Results:
- Mepolizumab reduced asthma exacerbation rates by approximately 50%.
- Mepolizumab significantly decreased oral prednisone requirements by a median of 50%.
- Treatment was effective in patients with persistent eosinophilic inflammation and frequent exacerbations.
Conclusions:
- Mepolizumab presents a significant new treatment option for severe, eosinophilic asthma.
- These findings support the use of mepolizumab for patients with unmet needs in asthma management.
- Data from MENSA, SIRIUS, and the DREAM study form the basis for regulatory submissions.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
01:19Antiasthma Drugs: Leukotriene Modifiers
2.3K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.3K
01:24Antiasthma Drugs: Methylxanthines
2.1K
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
2.1K
01:30Asthma-IV: Diagnostic and Management
3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
01:26COPD: Management Using Bronchodilators and Corticosteroids
1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
01:20Asthma: Pathogenesis and Management
1.7K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.7K